These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 27582008)

  • 1. Target DNA recognition and cleavage by a reconstituted Type I-G CRISPR-Cas immune effector complex.
    Majumdar S; Ligon M; Skinner WC; Terns RM; Terns MP
    Extremophiles; 2017 Jan; 21(1):95-107. PubMed ID: 27582008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR RNA-guided DNA cleavage by reconstituted Type I-A immune effector complexes.
    Majumdar S; Terns MP
    Extremophiles; 2019 Jan; 23(1):19-33. PubMed ID: 30284045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three CRISPR-Cas immune effector complexes coexist in Pyrococcus furiosus.
    Majumdar S; Zhao P; Pfister NT; Compton M; Olson S; Glover CV; Wells L; Graveley BR; Terns RM; Terns MP
    RNA; 2015 Jun; 21(6):1147-58. PubMed ID: 25904135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA targeting by the type I-G and type I-A CRISPR-Cas systems of Pyrococcus furiosus.
    Elmore J; Deighan T; Westpheling J; Terns RM; Terns MP
    Nucleic Acids Res; 2015 Dec; 43(21):10353-63. PubMed ID: 26519471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primed CRISPR DNA uptake in Pyrococcus furiosus.
    Garrett S; Shiimori M; Watts EA; Clark L; Graveley BR; Terns MP
    Nucleic Acids Res; 2020 Jun; 48(11):6120-6135. PubMed ID: 32421777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA.
    Fonfara I; Richter H; Bratovič M; Le Rhun A; Charpentier E
    Nature; 2016 Apr; 532(7600):517-21. PubMed ID: 27096362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CRISPR-associated Csx1 protein of Pyrococcus furiosus is an adenosine-specific endoribonuclease.
    Sheppard NF; Glover CV; Terns RM; Terns MP
    RNA; 2016 Feb; 22(2):216-24. PubMed ID: 26647461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system.
    Elmore JR; Sheppard NF; Ramia N; Deighan T; Li H; Terns RM; Terns MP
    Genes Dev; 2016 Feb; 30(4):447-59. PubMed ID: 26848045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RNA- and DNA-targeting CRISPR-Cas immune systems of Pyrococcus furiosus.
    Terns RM; Terns MP
    Biochem Soc Trans; 2013 Dec; 41(6):1416-21. PubMed ID: 24256230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A type III-B CRISPR-Cas effector complex mediating massive target DNA destruction.
    Han W; Li Y; Deng L; Feng M; Peng W; Hallstrøm S; Zhang J; Peng N; Liang YX; White MF; She Q
    Nucleic Acids Res; 2017 Feb; 45(4):1983-1993. PubMed ID: 27986854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target RNA capture and cleavage by the Cmr type III-B CRISPR-Cas effector complex.
    Hale CR; Cocozaki A; Li H; Terns RM; Terns MP
    Genes Dev; 2014 Nov; 28(21):2432-43. PubMed ID: 25367038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cas3 is a limiting factor for CRISPR-Cas immunity in Escherichia coli cells lacking H-NS.
    Majsec K; Bolt EL; Ivančić-Baće I
    BMC Microbiol; 2016 Mar; 16():28. PubMed ID: 26956996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the CRISPR-Cas RNA silencing Cmr complex bound to a target analog.
    Osawa T; Inanaga H; Sato C; Numata T
    Mol Cell; 2015 May; 58(3):418-30. PubMed ID: 25921071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular insights into DNA interference by CRISPR-associated nuclease-helicase Cas3.
    Gong B; Shin M; Sun J; Jung CH; Bolt EL; van der Oost J; Kim JS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(46):16359-64. PubMed ID: 25368186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic determinants of PAM-dependent DNA targeting and pre-crRNA processing in Sulfolobus islandicus.
    Peng W; Li H; Hallstrøm S; Peng N; Liang YX; She Q
    RNA Biol; 2013 May; 10(5):738-48. PubMed ID: 23392249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex.
    Takeshita D; Sato M; Inanaga H; Numata T
    J Mol Biol; 2019 Feb; 431(4):748-763. PubMed ID: 30639408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragmentation of the CRISPR-Cas Type I-B signature protein Cas8b.
    Richter H; Rompf J; Wiegel J; Rau K; Randau L
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2993-3000. PubMed ID: 28238733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of the Cmr2-Cmr3 subcomplex in the CRISPR-Cas RNA silencing effector complex.
    Osawa T; Inanaga H; Numata T
    J Mol Biol; 2013 Oct; 425(20):3811-23. PubMed ID: 23583914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple mechanisms for CRISPR-Cas inhibition by anti-CRISPR proteins.
    Bondy-Denomy J; Garcia B; Strum S; Du M; Rollins MF; Hidalgo-Reyes Y; Wiedenheft B; Maxwell KL; Davidson AR
    Nature; 2015 Oct; 526(7571):136-9. PubMed ID: 26416740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cmr4 is the slicer in the RNA-targeting Cmr CRISPR complex.
    Zhu X; Ye K
    Nucleic Acids Res; 2015 Jan; 43(2):1257-67. PubMed ID: 25541196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.